Answers are grounded in this paper and cite their sources.
Shows effective seizure control in a patient with Menkes disease, suggesting a new treatment option.
Genetic variants in ATP7A are associated with a spectrum of X-linked copper metabolism disorders. Menkes disease (MD) is the most severe form of ATP7A-related disorders, characterized by severe central nervous system degeneration and connective tissue abnormalities. Intractable epilepsy is a hallmark of MD, typically progressing through epileptic spasms resistant to antiseizure drugs. Here, we report a severe case of MD with a novel splice variant (c.2782-3T>G) that was successfully treated with perampanel. Case presentation: The patient developed epileptic spasms during early infancy and his initial electroencephalography revealed hypsarrhythmia. As his seizures were refractory to many antiseizure drugs and thyrotropin-releasing hormone therapy, he underwent adrenocorticotropic hormone therapy; however, this treatment was ineffective and caused various side effects. Eventually, perampanel was initiated, resulting in the cessation of seizures and improvement in electroencephalography findings. Discussion: This is the first reported case of MD successfully treated with perampanel, suggesting that perampanel may be a potential therapeutic option for intractable epilepsy with MD. Splice-site and intronic variants reportedly are more prevalent in milder forms of ATP7A-related disorders. The novel splice variant identified in the present case expands the understanding of intronic variation in ATP7A-related disorders.
No takes yet. Share an insight, caveat, or question.
Yoshida et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: